MY197202A - A liquid formulation of anti-tnf alpha antibody - Google Patents
A liquid formulation of anti-tnf alpha antibodyInfo
- Publication number
- MY197202A MY197202A MYPI2019005331A MYPI2019005331A MY197202A MY 197202 A MY197202 A MY 197202A MY PI2019005331 A MYPI2019005331 A MY PI2019005331A MY PI2019005331 A MYPI2019005331 A MY PI2019005331A MY 197202 A MY197202 A MY 197202A
- Authority
- MY
- Malaysia
- Prior art keywords
- liquid formulation
- tnf alpha
- alpha antibody
- antibody
- tnf
- Prior art date
Links
- 239000012669 liquid formulation Substances 0.000 title abstract 3
- 229960002964 adalimumab Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464436—Cytokines
- A61K39/464438—Tumor necrosis factors [TNF], CD70
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention relates to a liquid formulation of an anti-TNF-? antibody, specifically to a liquid formulation of adalimumab. The most illustrative drawing: FIGURE 2
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20170033188 | 2017-03-16 | ||
PCT/KR2018/003097 WO2018169348A1 (en) | 2017-03-16 | 2018-03-16 | Liquid formulation of anti-tnf alpha antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
MY197202A true MY197202A (en) | 2023-05-31 |
Family
ID=63522490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI2019005331A MY197202A (en) | 2017-03-16 | 2018-03-16 | A liquid formulation of anti-tnf alpha antibody |
Country Status (15)
Country | Link |
---|---|
JP (2) | JP7109849B2 (en) |
KR (2) | KR20180106974A (en) |
CN (1) | CN110621303A (en) |
AU (1) | AU2018236651B2 (en) |
BR (1) | BR112019019162A2 (en) |
CO (1) | CO2019010860A2 (en) |
MA (1) | MA46988A1 (en) |
MX (1) | MX2019010895A (en) |
MY (1) | MY197202A (en) |
NZ (1) | NZ757965A (en) |
PH (1) | PH12019502075A1 (en) |
RU (1) | RU2756619C2 (en) |
UA (1) | UA123847C2 (en) |
WO (1) | WO2018169348A1 (en) |
ZA (1) | ZA201906696B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20210114989A (en) | 2019-02-18 | 2021-09-24 | 일라이 릴리 앤드 캄파니 | therapeutic antibody formulation |
CA3133577A1 (en) * | 2019-03-18 | 2020-09-24 | Alvotech Hf | Aqueous formulations of tnf-alpha antibodies in high concentrations |
US11596690B2 (en) * | 2019-03-21 | 2023-03-07 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-IL-33 antibodies |
WO2021164717A1 (en) * | 2020-02-20 | 2021-08-26 | 百奥泰生物制药股份有限公司 | ANTI-TNF-α ANTIBODY PREPARATION, PREPARATION METHOD THEREFOR AND USE THEREOF |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5919606B2 (en) * | 2010-11-11 | 2016-05-18 | アッヴィ バイオテクノロジー リミテッド | Improved high concentration anti-TNF alpha antibody liquid formulation |
UY34105A (en) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | STABLE LIQUID FORMULATION OF ETANERCEPT |
BR112014021325A2 (en) * | 2012-03-07 | 2017-08-22 | Cadila Healthcare Ltd | LIQUID PHARMACEUTICAL FORMULATION AND LYOPHILIZED FORMULATION |
PE20191815A1 (en) * | 2012-09-07 | 2019-12-27 | Coherus Biosciences Inc | STABLE AQUEOUS FORMULATIONS OF ADALIMUMAB |
CA2898262A1 (en) * | 2013-01-24 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Tnf-alpha antigen-binding proteins |
JP2016515515A (en) * | 2013-03-15 | 2016-05-30 | バイエル・ヘルスケア・エルエルシーBayer HealthCare LLC | Anti-prolactin receptor antibody preparation |
US20150274819A1 (en) * | 2014-03-03 | 2015-10-01 | La Jolla Biologics, Inc. | Stable aqueous recombinant protein formulations |
IN2014MU01248A (en) * | 2014-04-02 | 2015-10-09 | Intas Pharmaceuticals Ltd | |
DK2946765T3 (en) * | 2014-05-23 | 2016-10-31 | Ares Trading Sa | Liquid pharmaceutical composition |
US9821059B2 (en) * | 2014-10-17 | 2017-11-21 | Alteogen Inc. | Composition for stabilizing protein and pharmaceutical formulation comprising the same |
HUP1400510A1 (en) * | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Pharmaceutical anti-tnfalpha antibody formulation |
TW201636047A (en) * | 2015-01-28 | 2016-10-16 | 麥博賽恩斯有限公司 | Pharmaceutical formulations for anti-TNF-alpha antibodies |
WO2016162819A1 (en) * | 2015-04-07 | 2016-10-13 | Lupin Limited | Stable aqueous pharmaceutical composition of anti-tnf alpha antibody |
-
2018
- 2018-03-16 RU RU2019130728A patent/RU2756619C2/en active
- 2018-03-16 AU AU2018236651A patent/AU2018236651B2/en active Active
- 2018-03-16 MY MYPI2019005331A patent/MY197202A/en unknown
- 2018-03-16 KR KR1020180031016A patent/KR20180106974A/en active Application Filing
- 2018-03-16 UA UAA201909838A patent/UA123847C2/en unknown
- 2018-03-16 JP JP2019551275A patent/JP7109849B2/en active Active
- 2018-03-16 NZ NZ757965A patent/NZ757965A/en unknown
- 2018-03-16 WO PCT/KR2018/003097 patent/WO2018169348A1/en active Application Filing
- 2018-03-16 CN CN201880031705.6A patent/CN110621303A/en active Pending
- 2018-03-16 MA MA46988A patent/MA46988A1/en unknown
- 2018-03-16 BR BR112019019162A patent/BR112019019162A2/en active IP Right Grant
- 2018-03-16 MX MX2019010895A patent/MX2019010895A/en unknown
-
2019
- 2019-09-12 PH PH12019502075A patent/PH12019502075A1/en unknown
- 2019-09-30 CO CONC2019/0010860A patent/CO2019010860A2/en unknown
- 2019-10-10 ZA ZA2019/06696A patent/ZA201906696B/en unknown
-
2020
- 2020-08-05 KR KR1020200098144A patent/KR102342292B1/en active IP Right Grant
-
2022
- 2022-05-06 JP JP2022076654A patent/JP2022097600A/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
RU2019130728A3 (en) | 2021-04-16 |
RU2756619C2 (en) | 2021-10-04 |
BR112019019162A2 (en) | 2020-04-14 |
RU2019130728A (en) | 2021-04-16 |
PH12019502075A1 (en) | 2020-09-14 |
JP2022097600A (en) | 2022-06-30 |
MX2019010895A (en) | 2019-11-05 |
AU2018236651A1 (en) | 2019-10-31 |
CO2019010860A2 (en) | 2020-01-17 |
KR102342292B1 (en) | 2021-12-24 |
JP7109849B2 (en) | 2022-08-01 |
KR20180106974A (en) | 2018-10-01 |
AU2018236651B2 (en) | 2020-12-10 |
NZ757965A (en) | 2022-07-01 |
MA46988A1 (en) | 2020-06-30 |
KR20200096472A (en) | 2020-08-12 |
JP2020510079A (en) | 2020-04-02 |
CN110621303A (en) | 2019-12-27 |
WO2018169348A1 (en) | 2018-09-20 |
UA123847C2 (en) | 2021-06-09 |
ZA201906696B (en) | 2020-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500540A1 (en) | Anti-pd-1 antibodies and their uses | |
PH12019501357A1 (en) | Anti-ox40 antibodies and their uses | |
CL2022000448A1 (en) | Autoinjector (divisional application no. 201903061) | |
EP4257613A3 (en) | Bispecific checkpoint inhibitor antibodies | |
MX2020009649A (en) | Monoclonal antibodies against bcma. | |
PH12018502456A1 (en) | Anti-cd04 antibodies and their uses | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
EP4335874A3 (en) | Anti-hla-g antibodies and use thereof | |
MY190297A (en) | Anti-pd1 antibodies and methods of use | |
MX2020010951A (en) | Anti-hla-g antibodies and use thereof. | |
MX2017003478A (en) | Anti-fgfr2/3 antibodies and methods using same. | |
MY191581A (en) | Anti-pd-1 antibodies | |
WO2016061389A3 (en) | Anti-alpha-synuclein antibodies and methods of use | |
EA201791029A1 (en) | ANTIBODIES AGAINST INTERLEUKIN-33 AND THEIR APPLICATION | |
SG10201808259TA (en) | Anti-jagged1 antibodies and methods of use | |
PH12018550160A1 (en) | NEW ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS | |
PH12019502075A1 (en) | A liquid formulation of anti-tnf alpha antibody | |
MX2023006415A (en) | Antibodies, uses & methods. | |
ZA201800804B (en) | Novel anti-human gpvi antibodies and uses thereof | |
SG11201811429XA (en) | Flow reactor | |
PH12019502694A1 (en) | Anti-trkb antibodies | |
MX2018009218A (en) | Cgrp antibodies and uses thereof. | |
MY195448A (en) | New Anti-Sirpa Antibodies and Their Therapeutic Applications | |
MX2017016258A (en) | Aml antigens and uses thereof. |